Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. /CNW/ — Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth ...

- More than 8 in 10 (82 per cent) of those working in the drugs industry believe big pharma will be unable to innovate sufficiently from within to replace blockbuster drugs going off-patent - Almost 7 ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...